THRIVE Feasibility Trial

PHASE3CompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

September 29, 2022

Primary Completion Date

April 16, 2023

Study Completion Date

June 28, 2023

Conditions
Surgery--ComplicationsAnesthesia ComplicationAnesthesia AwarenessAnesthesia Emergence DeliriumAnesthesiaSurgeryQuality of LifePain, PostoperativeNausea, PostoperativeAnesthesia MorbidityDepressionSleep Disorders, Circadian Rhythm
Interventions
OTHER

Anesthetic technique Propofol TIVA

Propofol TIVA no inhaled agent

OTHER

Anesthetic technique inhaled agent

must administer inhaled agent.

Trial Locations (4)

19104

Hosptial of the University of Pennsylvania, Philadelphia

48109

University of Michigan, Ann Arbor

63110

Washington University School of Medicine, St Louis

94305

Stanford University, Stanford

All Listed Sponsors
collaborator

University of Michigan

OTHER

collaborator

University of Pennsylvania

OTHER

collaborator

Stanford University

OTHER

collaborator

Patient-Centered Outcomes Research Institute

OTHER

lead

Washington University School of Medicine

OTHER

NCT05346588 - THRIVE Feasibility Trial | Biotech Hunter | Biotech Hunter